Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Stock Short Interest Climbs 76.0%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 31,307 shares, a growth of 76.0% from the September 30th total of 17,790 shares. Based on an average trading volume of 54,073 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.7% of the shares of the company are sold short.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ:SHPH traded down $0.19 during midday trading on Tuesday, reaching $4.76. 6,330 shares of the company’s stock were exchanged, compared to its average volume of 755,935. The company’s 50 day simple moving average is $4.21 and its two-hundred day simple moving average is $7.08. Shuttle Pharmaceuticals has a 12 month low of $2.58 and a 12 month high of $44.40. The firm has a market capitalization of $22.66 million, a PE ratio of -0.26 and a beta of 0.11.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc (NASDAQ:SHPH) is a clinical-stage biopharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer. The company’s research is centered on radiosensitizers, drugs intended to make cancer cells more vulnerable to radiation while potentially limiting damage to surrounding healthy tissue.

Shuttle’s lead candidate is ropidoxuridine, also known as iododeoxyuridine or IUdR, an investigational radiosensitizing agent being evaluated for use with radiotherapy.